Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1971 1
1972 5
1973 7
1974 5
1975 6
1976 4
1977 2
1978 9
1979 7
1980 5
1981 10
1982 15
1983 10
1984 10
1985 10
1986 6
1987 9
1988 11
1989 3
1990 8
1991 11
1992 7
1993 1
1994 6
1995 3
1996 2
1997 2
1998 4
1999 4
2000 2
2001 14
2002 6
2003 5
2004 5
2005 6
2006 8
2007 13
2008 2
2009 8
2010 6
2011 7
2012 10
2013 4
2014 15
2015 22
2016 23
2017 17
2018 20
2019 18
2020 23
2021 16
2022 14
2023 13
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

447 results

Results by year

Filters applied: . Clear all
Page 1
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
Diabetic Retinopathy Clinical Research Network; Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Diabetic Retinopathy Clinical Research Network, et al. Among authors: jampol lm. N Engl J Med. 2015 Mar 26;372(13):1193-203. doi: 10.1056/NEJMoa1414264. Epub 2015 Feb 18. N Engl J Med. 2015. PMID: 25692915 Free PMC article. Clinical Trial.
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.
Jhaveri CD, Glassman AR, Ferris FL 3rd, Liu D, Maguire MG, Allen JB, Baker CW, Browning D, Cunningham MA, Friedman SM, Jampol LM, Marcus DM, Martin DF, Preston CM, Stockdale CR, Sun JK; DRCR Retina Network. Jhaveri CD, et al. Among authors: jampol lm. N Engl J Med. 2022 Aug 25;387(8):692-703. doi: 10.1056/NEJMoa2204225. Epub 2022 Jul 14. N Engl J Med. 2022. PMID: 35833805 Free PMC article. Clinical Trial.
Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Gross JG, Glassman AR, Liu D, Sun JK, Antoszyk AN, Baker CW, Bressler NM, Elman MJ, Ferris FL 3rd, Gardner TW, Jampol LM, Martin DF, Melia M, Stockdale CR, Beck RW; Diabetic Retinopathy Clinical Research Network. Gross JG, et al. Among authors: jampol lm. JAMA Ophthalmol. 2018 Oct 1;136(10):1138-1148. doi: 10.1001/jamaophthalmol.2018.3255. JAMA Ophthalmol. 2018. PMID: 30043039 Free PMC article. Clinical Trial.
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW; Diabetic Retinopathy Clinical Research Network. Wells JA, et al. Among authors: jampol lm. Ophthalmology. 2016 Jun;123(6):1351-9. doi: 10.1016/j.ophtha.2016.02.022. Epub 2016 Feb 27. Ophthalmology. 2016. PMID: 26935357 Free PMC article. Clinical Trial.
Reply.
Wells JA, Glassman AR, Ayala AR, Jampol LM. Wells JA, et al. Among authors: jampol lm. Ophthalmology. 2017 Jan;124(1):e5-e6. doi: 10.1016/j.ophtha.2016.04.032. Ophthalmology. 2017. PMID: 27993277 Free PMC article. No abstract available.
JIGSAW RETINOPATHY.
Marchese A, Harrell M Jr, Jampol LM, Jain N, O'Keefe GAD. Marchese A, et al. Among authors: jampol lm. Retina. 2024 Mar 1;44(3):545-549. doi: 10.1097/IAE.0000000000003910. Retina. 2024. PMID: 37607399 No abstract available.
Reply.
Wells JA, Glassman AR, Bressler NM, Ayala AR, Jampol LM. Wells JA, et al. Among authors: jampol lm. Ophthalmology. 2017 Apr;124(4):e38-e39. doi: 10.1016/j.ophtha.2016.08.032. Ophthalmology. 2017. PMID: 28335949 No abstract available.
Reply.
Wells JA, Glassman AR, Jampol LM, Ayala A, Bressler NM. Wells JA, et al. Among authors: jampol lm. Ophthalmology. 2017 Mar;124(3):e26-e27. doi: 10.1016/j.ophtha.2016.07.001. Ophthalmology. 2017. PMID: 28219510 No abstract available.
Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.
Maturi RK, Glassman AR, Josic K, Baker CW, Gerstenblith AT, Jampol LM, Meleth A, Martin DF, Melia M, Punjabi OS, Rofagha S, Salehi-Had H, Stockdale CR, Sun JK; DRCR Retina Network. Maturi RK, et al. Among authors: jampol lm. JAMA. 2023 Feb 7;329(5):376-385. doi: 10.1001/jama.2022.25029. JAMA. 2023. PMID: 36749332 Free PMC article.
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).
Glassman AR, Wells JA 3rd, Josic K, Maguire MG, Antoszyk AN, Baker C, Beaulieu WT, Elman MJ, Jampol LM, Sun JK. Glassman AR, et al. Among authors: jampol lm. Ophthalmology. 2020 Sep;127(9):1201-1210. doi: 10.1016/j.ophtha.2020.03.021. Epub 2020 Mar 29. Ophthalmology. 2020. PMID: 32402554 Free PMC article. Clinical Trial.
447 results